Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19;...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of VICO.ST is 32 and suggests 222% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell